Astrazeneca (AZN) Other Non Operating Income (2018 - 2026)

Astrazeneca's Other Non Operating Income history runs 9 years deep, the most recent figure standing at -$3.5 billion for Q1 2026.

• In Q1 2026, Other Non Operating Income fell 10.54% year-over-year to -$3.5 billion; the TTM figure through Mar 2026 stood at -$12.5 billion (up 25.83% YoY), while the FY2023 annual figure was -$7.9 billion, changed N/A from the prior year.
• Other Non Operating Income for Q1 2026 stood at -$3.5 billion, down from -$3.2 billion in the prior quarter.
• The five-year high for Other Non Operating Income was -$2.1 billion in Q1 2022, with the low at -$7.9 billion in Q4 2023.
• The 5-year median for Other Non Operating Income is -$2.9 billion (2024), against an average of -$3.5 billion.
• The sharpest annual moves came in 2022 and 2024: Other Non Operating Income slumped 57.6% in 2022, then fell 6.59% in 2024.
• Astrazeneca's Other Non Operating Income stood at -$2.1 billion in 2022, then plunged by 268.59% to -$7.9 billion in 2023, then jumped by 60.38% to -$3.1 billion in 2024, then fell by 1.41% to -$3.2 billion in 2025, then fell by 10.54% to -$3.5 billion in 2026.
• Business Quant data shows AZN's Other Non Operating Income at -$3.5 billion in Q1 2026, -$3.2 billion in Q1 2025, and -$3.1 billion in Q3 2024.